Ignacio Muñoz-Sanjuán

Author

Also Known As

I Munoz-Sanjuan, I. Munoz-Sanjuan, Ignacio MUñoz-Sanjuan, Ignacio Munoz-Sanjuan, Ignacio Munoz-Sanjuan (112471), Ignacio Munoz‐Sanjuan, Ignacio Muñoz-Sanjuán, Ignacio Muñoz-Sanjuan, Ignacio Muñoz-Sanjuán, Ignacio Muňoz-Sanjuan

135

Publications

Citations

H-Index

138

Concepts

All Affiliations

CHDI Foundation Evotec (Germany)IRBM Science Park Evotec (United Kingdom)University of Antwerp

About

Ignacio Muñoz-Sanjuán is an author at CHDI Foundation specializing in medicine, neuroscience, and neurodegenerative diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	45	2.8K
2	Natural Sciences	12	13	581
3	Social Sciences	12	12	1.1K
4	Biochemistry	11	11	505
5	Health Sciences	2	2	50

Ignacio Muñoz-Sanjuán

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Philip M. Smallwood, Ignacio Muñoz-Sanjuán, Patrick Tong, Proceedings of the National Academy of Sciences Acidic FgfBrain DevelopmentNeurodevelopmentCell ProliferationCell Growth	1996	396
Characterization of Neurophysiological and Behavioral Changes, MRI Brain Volumetry and 1H MRS in zQ175 Knock-In Mouse Model of Huntington's Disease Taneli Heikkinen, Kimmo Lehtimäki, Nina Vartiainen, PLoS ONE GeneticsDisease Gene IdentificationMri Brain VolumetryBehavioral PhenotypeHuntingtin Gene	2012	323
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease Bryan Zeitler, Steven Froelich, Kimberly Marlen, Nature Medicine Transcriptional RegulationNeurodegenerative DiseasesHuntington ’Genetic DisorderMedicine	2019	212
Human glia can both induce and rescue aspects of disease phenotype in Huntington disease Abdellatif Benraiss, Su Wang, Stephanie Herrlinger, Nature Communications	2016	194
Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric Indications James Bilsland, Alan Wheeldon, Andrew Mead, Neuropsychopharmacology Neurochemical AlterationsPsychoneuroimmunologyPsychopathologyPsychiatric IndicationsPsychiatry	2007	185
Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington’s Disease Roland W. Bürli, Christopher A. Luckhurst, Omar Aziz, Journal of Medicinal Chemistry Aldo-keto ReductaseMolecular BiologyChemical BiologyPotential TherapyPharmaceutical Chemistry	2013	147
Cell fate specification and competence by Coco, a maternal BMP, TGFβand Wnt inhibitor Esther Bell, Ignacio Muñoz-Sanjuán, Curtis R. Altmann, Development	2003	145
Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington’s disease Xiao‐Hong Lu, Virginia B. Mattis, Nan Wang, Science Translational Medicine	2014	133
Characterization of HTT Inclusion Size, Location, and Timing in the zQ175 Mouse Model of Huntington´s Disease: An In Vivo High-Content Imaging Study Nikisha Carty, Nadège Berson, Karsten Tillack, PLoS ONE Htt Inclusion SizeZq175 Mouse ModelSocial SciencesHuntingtin GeneExperimental Neuropathology	2015	125
Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington’s Disease Models Vahri Beaumont, Sheng Zhong, Hai Lin, Neuron Disease ModelsNeurodegenerative DiseasesMolecular NeuroscienceNeurobiology Of DiseaseHuntington ’	2016	120

Page 1